AMGN34:BVMF
Amgen Inc. BDR
94,50 BRL
0,00%
(0,00) 1 d.
13. 11., 17:53:47 GMT-3 · BRL
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre AMGN34…
Otvoriť
95,19 BRL
Vysoká
95,19 BRL
Nízka
93,86 BRL
Trh. kap.
251,89 mld.
Priem. obj.
491,00
Objem
315,00
Max. za 52 týž.
95,19 BRL
Min. za 52 týž.
47,76 BRL
Akcie v obehu
540,91 mil.
Počet zamestnancov
32 tis.
Otvoriť
95,19 BRL
Vysoká
95,19 BRL
Nízka
93,86 BRL
Trh. kap.
251,89 mld.
Priem. obj.
491,00
Objem
315,00
Max. za 52 týž.
95,19 BRL
Min. za 52 týž.
47,76 BRL
Akcie v obehu
540,91 mil.
Počet zamestnancov
32 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
NAI500
·
pred 16 hodinami
Two Medical Giants Diverge in Strategy as Investors Face a Choice Between Steady Returns and High Growth
The Motley Fool
·
pred 23 hodinami
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Investing.com
·
pred 2 dňami
Argus raises Amgen stock price target on pipeline strength
Yahoo Finance
·
pred 2 dňami
Amgen Inc. (AMGN) Stock Forecasts
Profil
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Informácie o subjekte Amgen Inc. BDR
Generálny riaditeľRobert A. Bradway
Zamestnanci31,5 tis.
Dátum založenia1980
Hlavné sídloThousand Oaks, Kalifornia, Spojené štáty americké
OdvetvieHealth Care
Odvetvie-
Webamgen.com